WMSA
UTHR icon

Weiss Multi-Strategy Advisers’s United Therapeutics UTHR Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-5,000
Closed -$643K – 542
2014
Q3 		$643K Buy
+5,000
New +$515K 0.02% 424

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Weiss Multi-Strategy Advisers's UTHR Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of United Therapeutics (UTHR) in Q1 2024, closing a stake of 12,000 shares — an estimated $2.64M sold.

Weiss Multi-Strategy Advisers first reported a position in UTHR in Q3 2013 and held it in 19 quarters. The position peaked at $4.01M in Q4 2021. 525 funds tracked by Wall St. Rank hold UTHR as of Q1 2024.

  • Weiss Multi-Strategy Advisers reported no remaining United Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 12,000 United Therapeutics shares in Q1 2024, an estimated $2.64M.
  • Weiss Multi-Strategy Advisers first reported a position in United Therapeutics in Q3 2013 and held it in 19 quarters.
  • Weiss Multi-Strategy Advisers's United Therapeutics position peaked at $4.01M in Q4 2021.
  • 525 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.